Terms: = Leukemia AND SET, I2PP2A, 6418, ENSG00000119335, TAF-IBETA, PHAPII, IGAAD, 2PP2A AND Treatment
1017 results:
1. Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model.
Archer KJ; Fu H; Mrózek K; Nicolet D; Mims AS; Uy GL; Stock W; Byrd JC; Hiddemann W; Braess J; Spiekermann K; Metzeler KH; Herold T; Eisfeld AK
J Hematol Oncol; 2024 May; 17(1):28. PubMed ID: 38702786
[TBL] [Abstract] [Full Text] [Related]
2. [Correlation of
Wang LY; Jiang PF; Li JZ; Chen YX; Hu JD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):395-401. PubMed ID: 38660842
[TBL] [Abstract] [Full Text] [Related]
3. Construction and experimental validation of a novel ferroptosis-related gene signature for myelodysplastic syndromes.
Zhu Y; He J; Wei R; Liu J
Immun Inflamm Dis; 2024 Apr; 12(4):e1221. PubMed ID: 38578040
[TBL] [Abstract] [Full Text] [Related]
4. Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy.
de Camargo Magalhães ES; Hubner SE; Brown BD; Qiu Y; Kornblau SM
Leukemia; 2024 May; 38(5):1046-1056. PubMed ID: 38531950
[TBL] [Abstract] [Full Text] [Related]
5. Gut microbial dysbiosis in the pathogenesis of leukemia: an immune-based perspective.
Goswami M; Bose PD
Exp Hematol; 2024 May; 133():104211. PubMed ID: 38527589
[TBL] [Abstract] [Full Text] [Related]
6. Prediction of metabolites associated with somatic mutations in cancers by using genome-scale metabolic models and mutation data.
Lee G; Lee SM; Lee S; Jeong CW; Song H; Lee SY; Yun H; Koh Y; Kim HU
Genome Biol; 2024 Mar; 25(1):66. PubMed ID: 38468344
[TBL] [Abstract] [Full Text] [Related]
7. An ensemble-acute lymphoblastic leukemia model for acute lymphoblastic leukemia image classification.
Huang ML; Huang ZB
Math Biosci Eng; 2024 Jan; 21(2):1959-1978. PubMed ID: 38454670
[TBL] [Abstract] [Full Text] [Related]
8. Characterization of BCL-X L , MCL-1, and BAX Protein Expression in Response to Neoadjuvant Chemotherapy in Breast Cancer.
Saleh T; Al Shboul S; Awad H; El-Sadoni M; Alhesa A; Alsharaiah E; Abu Shahin N; Alotaibi MR; Battah A; Azab B
Appl Immunohistochem Mol Morphol; 2024 Apr; 32(4):189-199. PubMed ID: 38426376
[TBL] [Abstract] [Full Text] [Related]
9. HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer.
Saigí M; Mate JL; Carcereny E; Martínez-Cardús A; Esteve A; Andreo F; Centeno C; Cucurull M; Mesia R; Pros E; Sanchez-Cespedes M
Lung Cancer; 2024 Mar; 189():107502. PubMed ID: 38359742
[TBL] [Abstract] [Full Text] [Related]
10. Glasdegib with intensive/nonintensive chemotherapy in Japanese patients with untreated acute myeloid leukemia or high-risk myelodysplastic syndromes.
Izutsu K; Ubukawa K; Morishita T; Onishi Y; Ishizawa K; Fujii Y; Kimura N; Yokochi M; Naoe T
Cancer Sci; 2024 Apr; 115(4):1250-1260. PubMed ID: 38327103
[TBL] [Abstract] [Full Text] [Related]
11. Exploring risk factors and molecular targets in leukemia patients with COVID-19: a bioinformatics analysis of differential gene expression.
Ullah MA; Moin AT; Nipa JF; Islam NN; Johora FT; Chowdhury RH; Islam S
J Leukoc Biol; 2024 Mar; 115(4):723-737. PubMed ID: 38323674
[TBL] [Abstract] [Full Text] [Related]
12. A Comprehensive Metabolism-Related Gene Signature Predicts the Survival of Patients with Acute Myeloid leukemia.
Zhai Y; Shen H; Wei H
Genes (Basel); 2023 Dec; 15(1):. PubMed ID: 38254953
[TBL] [Abstract] [Full Text] [Related]
13. A comprehensive study for selecting optimal treatment modalities for blood cancer in a Fermatean fuzzy dynamic environment.
Alghazzawi D; Noor A; Alolaiyan H; El-Wahed Khalifa HA; Alburaikan A; Dai S; Razaq A
Sci Rep; 2024 Jan; 14(1):1896. PubMed ID: 38253693
[TBL] [Abstract] [Full Text] [Related]
14. Prediction of severe infections in chronic lymphocytic leukemia: a simple risk score to stratify patients at diagnosis.
Murru R; Galitzia A; Barabino L; Presicci R; La Nasa G; Caocci G
Ann Hematol; 2024 May; 103(5):1655-1664. PubMed ID: 38236391
[TBL] [Abstract] [Full Text] [Related]
15. Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance.
Maruyama D; Omi A; Nomura F; Touma T; Noguchi Y; Takebe K; Izutsu K
Int J Hematol; 2024 Feb; 119(2):146-155. PubMed ID: 38195971
[TBL] [Abstract] [Full Text] [Related]
16. Multiple machine-learning tools identifying prognostic biomarkers for acute Myeloid leukemia.
Cheng Y; Yang X; Wang Y; Li Q; Chen W; Dai R; Zhang C
BMC Med Inform Decis Mak; 2024 Jan; 24(1):2. PubMed ID: 38167056
[TBL] [Abstract] [Full Text] [Related]
17. Targeting of the CD161 inhibitory receptor enhances T-cell-mediated immunity against hematological malignancies.
Alvarez Calderon F; Kang BH; Kyrysyuk O; Zheng S; Wang H; Mathewson ND; Luoma AM; Ning X; Pyrdol J; Cao X; Suvà ML; Yuan GC; Wittrup KD; Wucherpfennig KW
Blood; 2024 Mar; 143(12):1124-1138. PubMed ID: 38153903
[TBL] [Abstract] [Full Text] [Related]
18. Investigation of fatty acid metabolism in chronic lymphocytic leukemia to guide clinical outcome and therapy.
Pan B; Xu Z; Du K; Gao R; Zhang J; Yin H; Shen H; Liang J; Li Y; Wang L; Li J; Xu W; Wu J
Ann Hematol; 2024 Apr; 103(4):1241-1254. PubMed ID: 38150112
[TBL] [Abstract] [Full Text] [Related]
19.
Choi YJ; Min YK; Lee ST; Choi JR; Shin S
Ann Lab Med; 2024 Jul; 44(4):335-342. PubMed ID: 38145892
[TBL] [Abstract] [Full Text] [Related]
20. Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Russo D; Schmitt M; Pilorge S; Stelljes M; Kawakita T; Teal VL; Haber B; Bopp C; Dadwal SS; Badshah C
Lancet Haematol; 2024 Feb; 11(2):e127-e135. PubMed ID: 38142695
[TBL] [Abstract] [Full Text] [Related]
[Next]
